Elan likely to cut jobs
The realignment will result in the elimination of a number of positions and additional refinement to Elan’s commercial activities in Tysabri for Crohn’s disease. Elan has also decided
Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the use of its Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with either programmed cell death protein 1 (PD-1) or PD-L1 antibodies to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Under the agreement, Access MediQuip will provide device benefit management services to WellPoint members, including insurance authorization, logistics management, and claims processing for orthopedic, spinal, pain management and